Cost-Effectiveness of Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer Using Evidence from the CREST Trial

Using the Chest Radiotherapy Extensive Stage Small Cell Lung Cancer Trial (CREST) results, a partitioned survival model was developed to evaluate the cost-effectiveness of adding thoracic radiotherapy (TRT) to the standard treatment (ST) of chemotherapy and prophylactic cranial irradiation for extensive-stage small cell lung cancer patients. We found TRT to strongly dominate ST over the actual follow up interval of the CREST. The TRT incremental cost-effectiveness ratio became less favorable over a lifetime horizon.

http://ift.tt/2wCjpgn